Syngene International Limited — Call Transcript 2023

Jan 18, 2023

==> picture [106 x 27] intentionally omitted <==

Ref: Syn/CS/SE/Reg 30/2022-23/Jan/05

January 18, 2023

Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 8000 F +91 80 6775 8808 CIN: L85110KA1993PLC0149 www.syngeneintl.com

To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Intimation of Conference Call for Analysts and Investors

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Tuesday, January 24, 2023

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Digitally signed by PRIYADARSHINI MAHAPATRA DN: c=IN, o=Personal, PRIYADARSHIN pseudonym=bc2eb3d598e4b4695dfab584d8c4954317f2c9b276b0ead69f4b6de415c5150d, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef26229a00b5f7 23a1ef57ab0005, postalCode=751015, st=ODISHA, serialNumber=df67e39aa5435d22f718c22d0516d97afb1208536f4f18 I MAHAPATRA 60285e06c72d0c9992, cn=PRIYADARSHINI MAHAPATRA Date: 2023.01.18 14:49:07 +05'30'

__________________ Priyadarshini Mahapatra Company Secretary and Compliance Officer

INVESTOR CONFERENCE CALL INVITE

Q3 FY 2022-23

==> picture [594 x 151] intentionally omitted <==

Syngene’s Q3 FY2023 Results Conference Call

At 3:00 pm IST on 24[th] Jan 2023

The management team of Syngene International Limited (“Syngene”) will organize a conference call for Analysts and Investors on Tuesday, 24[th] January at 3.00 pm IST following the announcement of financial results for the quarter ended December 31, 2022.

The call will be initiated with a brief management discussion on the Q3 FY2023 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene’s Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Tuesday, 24thJanuary 2023
Time:	3:00 pm to 3:45 pm IST
Dial-in Numbers*
Primary Number	+91 22 6280 1279 / +91 22 7115 8180
International Numbers	USA – 18667462133UK – 08081011573Singapore – 8001012045Hong Kong – 800964448Australia – 1800053698
Pre-registration Facility(Diamond_Pass_™link)	Step 1: Pre-register here.You will receive a passcode and a pin for thecall on the registered email address.Step 2: Dial into the call on the Conference Call date, enter the passcode& pin as prompted. You will be directly connected to the call

*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time

Syngene International: Putting Science to Work

Page 1

INVESTOR CONFERENCE CALL INVITE

Q3 FY 2022-23

==> picture [594 x 151] intentionally omitted <==

Replay Facility Dial in numbers: +91 22 7194 5757 Playback ID: 82631 The replay facility will be available from 24th January 2023 till 31[st] January 2023 Conference Call Transcript Will be available within 7 working days of the call on the corporate website: https://syngeneintl.com/

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 5200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com

For further information, please contact:

Krishnan G Syngene International : +91 8068919807 :Krishnan.G@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forwardlooking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.

Syngene International: Putting Science to Work

Page 2